Drug Trial Radar · NCT06904235
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Jul 7, 2025
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Helsinn Healthcare SAIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed. The two substances are: palonosetron, an antagonist of 5 HT3 receptors, and fosnetupitant, an antagonist of NK1 receptors that transforms into netupitant in the body. The medication is administered through intravenous injection (IV- drip). This study is built from 2 parts: Part 1: phase 2, open label Part 2: phase 3 double blind The detailed description, study design, study milestones and eligibility criteria will reflect the Part 1 requirements
Conditions
- Nausea and Vomiting Chemotherapy-Induced
- Nausea Post Chemotherapy
Interventions
IV NEPA (fosnetupitant/palonosetron)Drug
In NEPA-22-01, different body weight-based dosages of IV NEPA will be applied to patients below and over 3 months of age: Formulation A (for patients ≥3 months of age; 235 mg fosnetupitant/1.5 mg palonosetron per vial) or Formulation B (for patients \<3 months of age; 235 mg fosnetupitant/2.5 mg palonosetron per vial).
Reference Treatment: IV ondansetron infusionDrug
IV Ondansetron Dosing Regimen * Day 1 (before start of chemotherapy): One 30-min infusion of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration) * Day 1 at 4 h and 8 h after the end of first administration: Two 30-min infusions of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)
Reference Treatment: IV fosaprepitant infusionDrug
Fosaprepitant IV Dosing Regimen * Patients aged 12 years to \<18 years: a single dose of IV fosaprepitant 150 mg * Patients aged 2 years to \<12 years: a single dose of IV fosaprepitant 4 mg/kg (maximum dose: 150 mg) * Patients aged 6 months to \<2 years: a single dose of IV fosaprepitant 5 mg/kg (maximum dose: 150 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- COHORT 1 Neptupitant exposure parameterTime frame: From time zero ( start of IV NEPA infusion) to maximum 168 hours
- COHORT 1 Neptupitant exposureTime frame: From time zero ( start of IV NEPA infusion) to maximum 168 hours
- COHORT 2 monitoring of AEs (safety and tolerability of IV NEPA)Time frame: Up to 31 days
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Aghia Sophia Children's Hospital, Pediatric Hematology/ Oncology Unit (POHemU)
Athens, Greece · Recruiting
"AHEPA" University General Hospital of Thessaloniki, 2nd Department of Pediatrics
Thessaloniki, Greece · Withdrawn
Department of Pediatrics, Oncology and Hematology University Children's Clinical Hospital them. Ludwik Zamenhof in Bialystok
Bialystok, Poland · Withdrawn
Department of Paediatrics, Haematology, Oncology and Rheumatology Voivodship Children's Hospital them. J. Brudziński
Bydgoszcz, Poland · Recruiting
Clinic of Pediatrics, Oncology and Hematology University Pediatric Center them M. Konopnicka SP ZOZ Central Clinical Hospital Medical University of Lodz
Lodz, Poland · Recruiting
University Children'S Hospital in Lublin, Department of Pediatric Hematology, Oncology, and Transplantology
Lublin, Poland · Not yet recruiting
Clinical Department of Paediatric Oncology and Haematology VOIVODSHIP SPECIALIST CHILDREN'S HOSPITAL them. prof. dr. Stanisław Popowski in Olsztyn
Olsztyn, Poland · Withdrawn
Department of Pediatric Oncology, Hematology and Transplantation Clinical Hospital them. Karol Jonscher Medical University them. Karol Marcinkowski in Poznań
Poznan, Poland · Recruiting
Department of Paediatrics and Paediatric Haemato-Oncology University Clinical Hospital No. 1 them. prof. Tadeusz Sokołowski Pomeranian Medical University
Szczecin, Poland · Withdrawn
Department of Paediatrics, Oncology and Paediatric Immunology, University Clinical Hospital No. 1 them. prof. Tadeusz Sokołowski Pomeranian Medical University in Szczecin
Szczecin, Poland · Withdrawn
Department of Oncology and Surgical Oncology for Children and Youth Institute Mother and Child
Warsaw, Poland · Recruiting
Department of Oncology Institute "Monument - Child Health Center"
Warsaw, Poland · Recruiting
Fundeni Clinical Institute, Pediatric Hematology and BMT
Bucharest, Romania · Recruiting
Oncology Institute "Prof. Dr. Al. Trestioreanu", Pediatric Oncology
Bucharest, Romania · Recruiting
Emergency Children's Hospital " Louis Turcanu, Oncology-Haematology and BMP department
Timișoara, Romania · Recruiting
Gazi University Gazi Hospital Children Hematology and Oncology
Ankara, Turkey (Türkiye) · Recruiting
Hacettepe University Hospitals Oncology Hospital 2nd Floor Children Oncology
Ankara, Turkey (Türkiye) · Recruiting
Istanbul University Istanbul Faculty of Medicine Topkapı
Istanbul, Faith, Turkey (Türkiye) · Not yet recruiting
Ankara University Faculty of Medicine Children's Hospital, Department of Children Oncology and Hematology
Ankara, Mamak, Turkey (Türkiye) · Recruiting
Erciyes University Hospitals Kanka Children's Hematology Oncology and Bone Marrow Hospital
Kayseri, Melikgazi, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.